Khosla Ventures Acquisition Co

Khosla Ventures Acquisition — Valo Health — SPAC Merger (May 2021)

9 slides from Khosla Ventures Acquisition's SPAC merger presentation, May 28, 2021

  1. Slide 1: Valo Overview: Supplemental Content 2Q21

    Valo Overview: Supplemental Content 2Q21

  2. Slide 2: Disclaimer

    Disclaimer Disclaimer. This presentation (“Presentation ”) is for informational purposes only to assist interested parties in making their own evaluation with respect to the proposed business combination (the “Business Combination”) between Khosla Ventures Acquisition Co. (“Khosla”) and Valo Health,

  3. Slide 3: Disclaimer (con't)

    Disclaimer (con’t) Participants in the Solicitation. Khosla, Valo and their respective directors and executive officers may be deemed participants in the solicitation of proxies from Khosla’s shareholders with respect to the proposed Business Combination. A list of the names of Khosla’s directors and

  4. Slide 4: Risk Factors

    Risk Factors The below list of risk factors has been prepared as part of the Business Combination. The risks presented below are a subset of the general risks related to the business of Valo and the proposed Business Combination, and such list is not exhaustive. The list below has been prepared sole

  5. Slide 5: Valo by the numbers: Interfacing technology and therapeutic development to drive drug discovery

    Valo by the numbers: Interfacing technology and therapeutic development to drive drug discovery and development CUMULATIVE PROGRESS 2019 2020 2021 Targets evaluated 16 94 202 Discovery programs1 0 5 14 IND-enabling programs 0 0 12 Clinical programs 0 0 23 Patents and applications4 5 319 605 Targets

  6. Slide 6: Since our Series B, we have focused on scaling our internal supply chain of programs

    Since our Series B, we have focused on scaling our internal supply chain of programs EXPECTED SEC FILING SERIES B Mid June SPAC MERGER 10-year biobank partnership signed S1P1 (OPL-0301) ROCKi (OPL-0401) w/exclusivity window in-license complete in-license complete Additional preclinical Additional pr

  7. Slide 7: Valo's in-licensed assets are pursuing significant unmet medical needs in major diseases

    Valo’s in-licensed assets are pursuing significant unmet medical needs in major diseases OPL-0301 for the treatment of Post-MI & AKI OPL-0401 for the treatment of diabetic retinopathy (DR) Valo believes that as a biased S1P1 agonist, OPL-0301 may avoid the side effects Valo believes that OPL-0401’s o

  8. Slide 8: Valo aspires to significantly reduce the time and cost of drug discovery and development

    In the long-term, Valo aspires to significantly reduce the time and cost of drug discovery and development, while improving the quality and PTRS of its programs DISCOVERY & PRECLINICAL CLINICAL DEVELOPMENT APPROVAL TOTAL INDUSTRY1 AVERAGE AVERAGE AVERAGE AVERAGE 5.5 years 6.5 years 1.5 years 13.5 yea

  9. Slide 9: Slide 9

Valo Health — SPAC Merger (May 2021) on 6ix